Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoGen Inc (NASDAQ:IMGN)

2.00
Delayed Data
As of 3:59pm ET
 +0.12 / +6.38%
Today’s Change
1.51
Today|||52-Week Range
14.10
-85.26%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$164.1M

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. Its also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. The company was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Other institutional52.53%
Mutual fund holders34.61%
Individual stakeholders1.34%

Top Executives

Mark J. EnyedyPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Richard J. GregoryChief Scientific Officer & Executive VP
John M. LambertExecutive Vice President
Craig BarrowsSecretary, Vice President & General Counsel